The COVID-19 vaccine developed by Pfizer and BioNTech is more likely to shield in opposition to a extra infectious variant of the virus, which was found in Britain and has unfold world wide, in response to outcomes of additional lab checks launched on Wednesday.
The encouraging outcomes, primarily based on an evaluation of blood of individuals in trials, are primarily based on extra in depth evaluation than these launched by the US drugmaker final week.
Last week, Pfizer mentioned an analogous laboratory examine confirmed the vaccine was efficient in opposition to one key mutation, known as N501Y, present in each of the extremely transmissible new variants spreading in Britain and South Africa.
The newest examine, which has not but been peer reviewed, was carried out on 10 mutations, that are attribute of the variant often known as B117 recognized in Britain.
(Except for the headline, this story has not been edited by LiveNews360 workers and is printed from a syndicated feed.)